Search

Your selection

Clear all

Filter by category

Filter by content type

Filter by content year

News

Vaxart to Host Virtual Stockholder Fireside Chat on Wednesday, August 20 to Discuss Reverse Stock Split Proposal

August 14, 2025 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results

August 13, 2025 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; that the … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart CEO Issues Letter to Stockholders

August 8, 2025 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart to Host Second Quarter 2025 Business Update and Financial Results Conference Call on August 13

August 6, 2025 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq

July 24, 2025 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart Announces Trading on OTCQX Best Market

July 8, 2025 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders

June 13, 2025 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

June 11, 2025 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … regarding clinical results and trial data, including their design, and the timing of such trials and of receiving and … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by …
News

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

June 10, 2025 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart Announces Adjournment of Annual Meeting of Stockholders

June 2, 2025 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
Scroll to Top